Diabetes Draft Guidance May Require Extended Trial Length, Participation

A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet